Precision Medicine Online

CorrectSeq Eyes Overseas Sickle-Cell Trials for Base-Editing Therapy After Early Success

CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...
Seeking Alpha

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its ...
Morningstar

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational ...

GEB-101, a wholly owned program of GenEditBio, is a genome editing drug candidate designed as a once-and-done treatment for TGFBI corneal dystrophy. GEB-101 is based on the CRISPR-Cas genome editing ...